Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-919-6364530
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable
Fennec Pharmaceuticals (TSE:FRX) Frequently Asked Questions
What is Fennec Pharmaceuticals' stock symbol?
Fennec Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "FRX."
How were Fennec Pharmaceuticals' earnings last quarter?
Fennec Pharmaceuticals Inc (TSE:FRX) released its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. View Fennec Pharmaceuticals' Earnings History.
When is Fennec Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for Fennec Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fennec Pharmaceuticals.
Has Fennec Pharmaceuticals been receiving favorable news coverage?
News stories about FRX stock have trended positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Fennec Pharmaceuticals earned a daily sentiment score of 2.2 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Fennec Pharmaceuticals.
Who are some of Fennec Pharmaceuticals' key competitors?
Some companies that are related to Fennec Pharmaceuticals include Monash IVF Group (MVF), Senesco Technologies (ELOX), Emerald Health Therapeutics (EMH), Rafael (RFL), Paradigm Biopharmaceuticals (PAR), Emblem (EMC), 22nd Century Group (XXII), Horizon Discovery Group (HZD), CEL-SCI (CVM), CorMedix (CRMD), CorMedix (CRMD), Acasti Pharma (ACST), Botanix Pharmaceuticals (BOT), IMV (IMV) and Bioventix (BVXP).
Who are Fennec Pharmaceuticals' key executives?
Fennec Pharmaceuticals' management team includes the folowing people:
- Mr. Rostislav Raykov, CEO & Director (Age 43)
- Mr. Robert C. Andrade, Chief Financial Officer (Age 44)
- Mr. Mark Gowland, Controller
- Mr. Lei Fang, Pres of Pharstat Inc
- Ms. Anne McKay, Regulatory Consultant (Age 65)
How do I buy shares of Fennec Pharmaceuticals?
Shares of FRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Fennec Pharmaceuticals' stock price today?
One share of FRX stock can currently be purchased for approximately C$5.25.
How big of a company is Fennec Pharmaceuticals?
What is Fennec Pharmaceuticals' official website?
How can I contact Fennec Pharmaceuticals?
Fennec Pharmaceuticals' mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company can be reached via phone at +1-919-6364530.
MarketBeat Community Rating for Fennec Pharmaceuticals (TSE FRX)
MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
